The benefits of sodium/glucose cotransporter 2 (SGLT2) inhibitors seem to extend beyond glycemic control. We review recent randomized trial evidence evaluating SGLT2 inhibition in nondiabetic settings, including in patients with chronic kidney disease (CKD) and heart failure (HF).

中文翻译：

---

慢性肾病和心力衰竭中的钠/葡萄糖协同转运蛋白 2 抑制剂：为非糖尿病患者准备好黄金时间。

钠/葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂的益处似乎超出了血糖控制范围。我们回顾了最近在非糖尿病环境中评估 SGLT2 抑制的随机试验证据，包括慢性肾病 (CKD) 和心力衰竭 (HF) 患者。